Model-Based Compliance Discrimination via Soft Tactile Optical Sensing and Optical Flow Computation: A Biomimetic Approach

Soft tactile optical sensors have opened up new possibilities for endowing artificial robotic hands with advanced touch-related properties; however, their use for compliance discrimination has been poorly investigated and mainly relies on data-driven methods. Discrimination of object compliance is crucial for enabling accurate and purposeful object manipulation. Humans retrieve this information primarily using the contact area spread rate (CASR) over their fingertips. CASR can be defined as the integral of tactile flow, which describes the movement of iso-strain surfaces within the fingerpad. This work presents the first attempt to discriminate compliance through soft optical tactile sensing based on a computational model of human tactile perception that relies on CASR and tactile flow concepts. To this aim, we used a soft optical biomimetic sensor that transduces surface deformation via movements of marked pins, similar to the function of intermediate ridges in the human fingertip. We acquired images of markers' movements during the interaction with silicone specimens with different compliance at different indenting forces. Then, we computed the optical flow as a tactile flow approximation and its divergence to estimate the CASR. Our model-based approach can accurately discriminate the compliance levels of the specimens, both when the sensor probed the surface perpendicularly and with different inclinations. Finally, we used the relation between specimen compliance and the experimentally evaluated CASR to infer the compliance of a new specimen relying on the estimated CASR

Multiple sclerosis treatment and melanoma development

Therapy of multiple sclerosis (MS) with disease-modifying agents such as natalizumab or fingolimod has been associated with the development of cutaneous melanoma. Here we briefly revise literature data and report of a case of a 48-year old woman who developed a melanoma and several atypical naevi after sub sequential treatment with natalizumab (1 year) and fingolimod (7 years). By immunohistochemistry we observed the presence of T cells and leukocyte infiltration as well as of vascular endothelial growth factor (VEGF)-A expression in the patient melanoma biopsy. Then, we analyzed proliferation, migration and VEGF-A expression in three melanoma cell lines and found out that both natalizumab and fingolimod inhibited tumor cell proliferation but promoted or blocked cell migration depending on the cell line examined. VEGF-A secretion was augmented in one melanoma cell line only after fingolimod treatment. In conclusion, our in vitro data do not support the hypothesis of a direct action of natalizumab or fingolimod on melanoma progression but acting on the tumor microenvironment these treatments could indirectly favor melanoma evolution

Prognostic impact of Ki-67 proliferative index in resectable pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease characterized by complex biological features and poor prognosis. A prognostic stratification of PDAC would help to improve patient management. The aim of this study was to analyse the expression of Ki-67 in relation to prognosis in a cohort of patients with PDAC who had surgical treatment

Electrochemical synthesis of nanowire anodes from spent lithium ion batteries

A novel process is proposed to produce nanostructured batteries anodes from spent lithium-ion batteries. The electrodic powder recovered by the mechanical treatment of spent batteries was leached and the dissolved metals were precipitated as cobalt carbonates. Two different precipitation routes were separately tested producing cobalt carbonates with different Cu and Fe contents. Nanowire anodes were produced by electrodeposition into nanoporous alumina templates from the electrolytic baths prepared by dissolution of the precipitated carbonates. The electrochemical performances of the produced anodes were evaluated as compared to nanowire anodes produced with the same electrodeposition method but using a synthetic cobalt bath. The application of the carbonates produced by directly precipitating all the leached metals gave nanowires with capacity about halved as compared to the nanowires electrodeposited from the synthetic bath. Selectively removing Cu and Fe prior cobalt carbonate precipitation yielded, in contrast, nanowires with capacity initially larger and then gradually approaching that attained by the nanowire electrodeposited from the synthetic bath. A detailed analysis is presented describing the role of metallic impurities in determining the capacity of the produced nanowires. The impact of the illustrated results for the development of sustainable recycling processes of lithium-ion batteries is discussed

Regeneration of Exhausted Palladium-Based Membranes: Recycling Process and Economics

The aim of the present work is the recycling treatment of tubular α-Al2O3-supported ceramic membranes with a Pd/Ag selective layer, employed in hydrogen production with integrated CO2 capture. A nitric acid leaching treatment was investigated, and recovered ceramic supports were characterized, demonstrating their suitability for the production of novel efficient membranes. The main objective was the metal dissolution that preserved the support integrity in order to allow the recovered membrane to be suitable for a new deposition of the selective layer. The conditions that obtained a satisfactory dissolution rate of the Pd/Ag layer while avoiding the support to be damaged are as follows: nitric acid 3 M, 60 °C and 3.5 h of reaction time. The efficiency of the recovered supports was determined by nitrogen permeance and surface roughness analysis, and the economic figures were analysed to evaluate the convenience of the regeneration process and the advantage of a recycled membrane over a new membrane. The experimentation carried out demonstrates the proposed process feasibility both in terms of recycling and economic results.This research has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 760944 (MEMBER project)

Tildrakizumab in moderate-to-severe plaque psoriasis: A multicenter, retrospective, real-life study

New biologic agents targeting interleukin (IL)23/T-helper17 axis, such as tildrakizumab, have been developed for the treatment of plaque psoriasis. To analyze the efficacy and safety of tildrakizumab in a real life setting of patients affected by moderate-to-severe psoriasis over a 28-week treatment period. A multicentric retrospective study was conducted in patients who initiated tildrakizumab between February 2020 and March 2021. Psoriasis Area and Severity Index-PASI was measured at baseline and after 4, 16 and 28 weeks. The percentage change in PASI value from baseline to the considered time-points, proportion of patients with absolute PASI <3 at week 28 and the percentages of achieving a PASI75 or PASI90 response were assessed. Data about potential safety issues and adverse events (AEs) were collected. Statistical analysis were performed for establish clinical efficacy and for variables predicting clinical response. Fifty nine patients with psoriasis were included. Overall mean PASI percentage reduction was of 88% from baseline to week 28 and 47 out of 59 patients (79.7%) at week 28 had an absolute PASI <3. PASI75 and PASI90 responses at week 28 were achieved by 48 (81.40%) patients and 38 (64.4.0%) patients, respectively. No substantial associations between gender, body mass index - BMI, PASI at baseline and prior exposition to biological therapies and the efficacy endpoints were retrieved. No serious safety issues or discontinuations related to adverse events were reported. In our real-life study, tildrakizumab showed high efficacy and a favorable safety profile, regardless of patient- and disease-related factors

Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report

<p>Abstract</p> <p>Introduction</p> <p>Aggressive, recurrent embolisms require accurate etiologic diagnosis. We describe the case of a 69-year-old Italian Caucasian woman with recurrent arterial embolisms in whom several sources and triggers of thrombosis were detected.</p> <p>Case presentation</p> <p>The patient, a 69-year-old Italian Caucasian woman, presented with a systemic embolism that was initially attributed to atrial fibrillation. The recurrence of embolisms despite anti-thrombotic therapy prompted a re-evaluation of the clinical presentation. New potential causes of thrombosis emerged in this patient, including thrombocytosis associated with the <it>JAK2 V617F </it>mutation and the very rare mural thrombosis of the descending aorta. A mural thrombus in the pulmonary artery was detected contiguous with the aortic mural thrombosis, raising the possibility of a clinically silent ductus Botalli as the initiating event. The patient was treated with warfarin, aspirin, hydroxyurea, and surgery.</p> <p>Conclusions</p> <p>The diagnosis was achieved via systematic use of imaging procedures and reconsideration of blood tests performed to explore the diagnosis of thrombosis. This allowed a deeper and more detailed analysis of the case beyond the conventional approach, which would have aimed to identify one cause for the condition at hand, in this case, atrial fibrillation. The broader approach that we used resulted in the diagnosis of multiple embolisms from multiple sites and multiple causes.</p